Postprandial glycemic control using insulin aspart with NPH in inadequately controlled diabetics

National Medical Journal of China

Volumn 89, Issue 28, 2009, Pages 1960-1963

  Gao, Yan ^a   Pan, Chang Yu ^a   Zou, Da Jin ^a   Xu, Zhang Rong ^a   Liu, Xiao Min ^a   Guo, Xiao Hui ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

Diabetes mellitus,type 2; Hypoglycemia; Insulin; Intensive therapy

Indexed keywords

ANTIDIABETIC AGENT; DRUG DERIVATIVE; INSULIN; INSULIN ASPART; ISOPHANE INSULIN; PROTAMINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, NPH; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; PROTAMINES; YOUNG ADULT;

EID: 84871286740     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2009.28.008     Document Type: Article

References (20)

1. The DECODE Study group on behalf the European Diabetes Epidemiology Group. Glucose tolerance and mortality; comparison of WHO and American Diabetes Association diagnostic criteria. Lancet, 1999, 354: 617-621.
2. Bonora E, Muggeo M. Postprandial blood glucose as a risk factor for cardiovascular disease in type 2 diabetes: the epidemiological evidence. Diabetologia, 2001, 44: 2107-2114.
3. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and the progression of long-term complication in insulin-dependent diabetes mellitus. N Engl J Med, 1993, 329: 977-986.
4. UK Prospective Diabetes Study (UKPOS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS33). Lancet, 1998, 352: 837-853.
5. Heinemann L, Heise T, Jorgensen LN, et al. Action profile of the rapid acting insulin analogue: human insulin B28Asp. Diabet Med, 1993, 10: 535-539.
6. Lindholm A, McEwen J, Riis A. Improved postprandial glycaemic control with insulin aspart-a randomized double-blind cross-over trial in type 1 diabetes mellitus. Diabetes Care, 1999, 22: 801-805.
7. Gallagher A, Home PD. The effect of improved post-prandial blood glucose control on post-prandial metabolism and markers of vascular risk in people with type 2 diabetes. Diabetes Res Clin Pract, 2005, 67: 196-203.
8. Home PD, Lindholm A, Riis A. The european insulin aspart study group, insulin aspart vs. HI in the management of long-term blood glucose control in type 1 diabetes mellitus: a randomized controlled trial. Diabet Med, 2000, 17: 762-771.
9. Rosenfalck AM, Thorsby P, Kjems L, et al. Improved postprandial glycemic control with insulin aspart in type 2 diabetic patients treated with insulin. Acta Diabetol, 2000, 37: 41-46.
10. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med, 1998, 15: 539-553.
11. IDF Clinical Guidelines Task Force. global guideline for type 2 diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med, 2006, 23: 579-593.
12. European Diabetes Policy Group 1998. A desktop guide to type 1 (insulin-dependent) diabetes mellitus. Diabet Med, 1999, 16: 253-266.
13. American College of Endocrinology. ACE consensus statement on guideline for glycaemic control. Endocr Pract, 2002, 8: 40-82.
14. World Medical Association. Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. J Postgrad Med, 2002, 48: 206.
15. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care, 2006, 29: S4-S42.
16. Garber AJ, Moghissi ES, Bransome ED Jr, et al. American College of Endocrinology position statement on inpatient diabetes and metabolic control. Endocr Pract, 2004, 10: 77-82.
17. DCCT Research Group. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes, 1996, 45: 1289-1298.
18. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease. New Eng J Med, 2005, 353: 2643-2653.
19. Reynolds NA, Wagstaff AJ. Insulin aspart: a review of its use in the management of type 1 or 2 diabetes mellitus. Drugs, 2004, 64: 1957-1974.
20. Gerich JE. Hypoglycaemia and counterregulation in type 2 diabetes. Lancet, 2000, 356: 1946-1947.